

Apixaban SR Tablets (a 505B2 NDA Product)

Shashikanth Varala
Mobile: (+44)7505457665
Email: shashi@mahashiv.co.uk
Mahashiv Limited
Unit 1, Kataria Point, 1 Riches Road,
Illford, England, IG1 1JH

Rob Camerer
Mobile: (417) 770-4600
Tel: (417) 885-7000
Email: robcamerer@globalpharmapartners.com

Timelines for Developing Brand XXXXXX®

- Definitive Agreement – Q3 2023
- Completion of 3×3 exhibit (pivotal) batches of drug product: Q4 2023
- 6 Month stability completion: Q3 2024
- BE study completion: Q2 2024
- Estimated FDA filing date: Q3-4 2024
- FDA approval: Q4 2025

Terms for US Partner:

- Total Milestone payments: \$1,050,000
 - \$250,000 on signing
 - \$250,000 on Bioequivalence study Acceptance
 - \$275,000 on 505(b)(2) filing to FDA
 - \$275,000 on FDA Approval
- Filing Fee: Partner pays upfront (recoup 50% of fee from profits)
- Profit sharing: DP 50%/ 50% Partner
- Length of Term: 10 years

Estimated Remaining Development Costs (50% DP/50% Partner):

- Formulation Development Cost: \$500,000
- Submission batches: \$ 300,000 (India) (7 batches- 6 validation and one feasibility batches; includes API cost of \$80,000)
- Bioequivalence studies: \$500,000
- Stability & non-clinical studies: *\$200,000

+ Please note that the submission batches costs from India, should we move to EU/US CDMO, then costs will increase.

Estimated Commercial Finished Dose Cost

COG: \$15.00 per unit-dose pack (28s) includes packaging, shipping, insurance etc. Please note that these COGS are based on manufacturing in India, should we move manufacturing to EU/US CDMO, then costs will increase.

RLD PRODUCT NAME

Eliquis® Tablet, 2.5, 5 mg

API NAME

Apixaban

DOSAGE FORM

SR Tablets, 5 and 10 mg

INDICATION

Blood clot prevention

PATENT STATUS

Mahashiv owns Patent Pending for the product and technology

PARAGRAPH IV CERTIFICATION

NA

ANDA FILER

NA

POTENTIAL COMPETITORS

No generic competition

EARLIEST GENERIC LAUNCH

NA